vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Waters Corporation (WAT). Click either name above to swap in a different company.

Waters Corporation is the larger business by last-quarter revenue ($932.4M vs $3.2M, roughly 289.4× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — 598.5% vs 24.2%, a 574.3% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (262.0% vs 6.8%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs -73.4%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

LAB vs WAT — Head-to-Head

Bigger by revenue
WAT
WAT
289.4× larger
WAT
$932.4M
$3.2M
LAB
Growing faster (revenue YoY)
LAB
LAB
+255.2% gap
LAB
262.0%
6.8%
WAT
Higher net margin
LAB
LAB
574.3% more per $
LAB
598.5%
24.2%
WAT
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
-73.4%
LAB

Income Statement — Q4 2025 vs Q4 2025

Metric
LAB
LAB
WAT
WAT
Revenue
$3.2M
$932.4M
Net Profit
$19.3M
$225.2M
Gross Margin
83.5%
61.1%
Operating Margin
-578.6%
29.0%
Net Margin
598.5%
24.2%
Revenue YoY
262.0%
6.8%
Net Profit YoY
156.6%
-2.7%
EPS (diluted)
$0.05
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WAT
WAT
Q4 25
$3.2M
$932.4M
Q3 25
$19.6M
$799.9M
Q2 25
$21.8M
$771.3M
Q1 25
$40.8M
$661.7M
Q4 24
$890.0K
$872.7M
Q3 24
$22.1M
$740.3M
Q2 24
$22.5M
$708.5M
Q1 24
$45.5M
$636.8M
Net Profit
LAB
LAB
WAT
WAT
Q4 25
$19.3M
$225.2M
Q3 25
$-34.7M
$148.9M
Q2 25
$-33.5M
$147.1M
Q1 25
$-26.0M
$121.4M
Q4 24
$-34.1M
$231.4M
Q3 24
$-26.9M
$161.5M
Q2 24
$-45.7M
$142.7M
Q1 24
$-32.2M
$102.2M
Gross Margin
LAB
LAB
WAT
WAT
Q4 25
83.5%
61.1%
Q3 25
48.5%
59.0%
Q2 25
48.8%
58.3%
Q1 25
48.4%
58.2%
Q4 24
-202.8%
60.1%
Q3 24
54.9%
59.3%
Q2 24
46.1%
59.3%
Q1 24
53.1%
58.9%
Operating Margin
LAB
LAB
WAT
WAT
Q4 25
-578.6%
29.0%
Q3 25
-168.5%
24.0%
Q2 25
-118.1%
24.4%
Q1 25
-80.8%
22.9%
Q4 24
-1162.1%
33.5%
Q3 24
-120.9%
28.5%
Q2 24
-134.5%
26.7%
Q1 24
-132.2%
21.0%
Net Margin
LAB
LAB
WAT
WAT
Q4 25
598.5%
24.2%
Q3 25
-177.4%
18.6%
Q2 25
-153.7%
19.1%
Q1 25
-63.8%
18.3%
Q4 24
-3828.3%
26.5%
Q3 24
-122.0%
21.8%
Q2 24
-203.3%
20.1%
Q1 24
-70.6%
16.0%
EPS (diluted)
LAB
LAB
WAT
WAT
Q4 25
$0.05
$3.76
Q3 25
$-0.09
$2.50
Q2 25
$-0.09
$2.47
Q1 25
$-0.07
$2.03
Q4 24
$-0.06
$3.88
Q3 24
$-0.07
$2.71
Q2 24
$-0.12
$2.40
Q1 24
$-0.27
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$120.9M
$587.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$424.3M
$2.6B
Total Assets
$567.8M
$5.1B
Debt / EquityLower = less leverage
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WAT
WAT
Q4 25
$120.9M
$587.8M
Q3 25
$129.4M
$459.1M
Q2 25
$158.6M
$367.2M
Q1 25
$150.9M
$382.9M
Q4 24
$166.7M
$325.4M
Q3 24
$210.6M
$331.5M
Q2 24
$269.8M
$327.4M
Q1 24
$287.1M
$338.2M
Total Debt
LAB
LAB
WAT
WAT
Q4 25
$1.4B
Q3 25
Q2 25
Q1 25
Q4 24
$299.0K
$1.6B
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
WAT
WAT
Q4 25
$424.3M
$2.6B
Q3 25
$399.7M
$2.3B
Q2 25
$424.5M
$2.2B
Q1 25
$454.6M
$2.0B
Q4 24
$471.7M
$1.8B
Q3 24
$489.3M
$1.6B
Q2 24
$510.3M
$1.4B
Q1 24
$577.3M
$1.3B
Total Assets
LAB
LAB
WAT
WAT
Q4 25
$567.8M
$5.1B
Q3 25
$539.6M
$4.9B
Q2 25
$557.0M
$4.7B
Q1 25
$579.6M
$4.6B
Q4 24
$612.3M
$4.6B
Q3 24
$681.5M
$4.5B
Q2 24
$708.7M
$4.4B
Q1 24
$777.7M
$4.5B
Debt / Equity
LAB
LAB
WAT
WAT
Q4 25
0.55×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
0.89×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WAT
WAT
Operating Cash FlowLast quarter
$-1.2M
$164.6M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-51.7%
Capex IntensityCapex / Revenue
14.8%
Cash ConversionOCF / Net Profit
-0.06×
0.73×
TTM Free Cash FlowTrailing 4 quarters
$-82.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WAT
WAT
Q4 25
$-1.2M
$164.6M
Q3 25
$-22.2M
$187.3M
Q2 25
$-20.7M
$41.1M
Q1 25
$-30.3M
$259.6M
Q4 24
$-14.1M
$240.1M
Q3 24
$-27.9M
$204.6M
Q2 24
$-39.0M
$54.5M
Q1 24
$-62.5M
$262.9M
Free Cash Flow
LAB
LAB
WAT
WAT
Q4 25
$-1.7M
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
$-17.4M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
LAB
LAB
WAT
WAT
Q4 25
-51.7%
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
-1959.7%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
LAB
LAB
WAT
WAT
Q4 25
14.8%
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
380.0%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
LAB
LAB
WAT
WAT
Q4 25
-0.06×
0.73×
Q3 25
1.26×
Q2 25
0.28×
Q1 25
2.14×
Q4 24
1.04×
Q3 24
1.27×
Q2 24
0.38×
Q1 24
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons